Global Cancer Immunotherapy Market to Thrive on Increasing Prevalence of the Diseases and Increasing Death Rate

Globally, the need for cancer immunotherapy is increasing because of an expanding patient pool as well as a rising death rate. An increasing number of approvals for novel immunotherapeutic medicines is likely to drive expansion of the global cancer immunotherapy market. For pharmaceutical firms, cancer immunotherapy has come up as a new source of revenue. Immunotherapies are also in high demand due to side effects connected with traditional chemotherapies, such as organ failure and cancer recurrence, as well as a growing need for technologically sophisticated healthcare solutions. Furthermore, in addition to that, the development of novel medication classes, such as checkpoint inhibitors and multiple myeloma target receptors, is expected to pave the way for enhanced therapeutics in the market.

Some prominent players that are operating in the global cancer immunotherapy market include names such as F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Takeda Pharmaceuticals, Eli Lilly and Company, Merck & Co., Inc., and Spectrum Pharmaceuticals, Inc..

The opportunity in the global cancer immunotherapy market is likely to rise at a rate of 14.60% CAGR during the forecast period, from 2016 to 2024. The global cancer immunotherapy market is predicted to attain a value of around US$ 124.88 bn through 2024.

cancer immunotherapy market

Existence of Advanced Healthcare System to Drive Market in the North America

Since a long time, North America and Europe have dominated this sector. Both the regional markets are estimated to benefit from the existence of excellent healthcare and medical facilities. The North America market is expected to develop as the geriatric population grows, high prevalence of the disease, and new treatments become more widely available. In the next few years to come, continuous research initiatives for the development of novel cancer treatments are anticipated to help these regional markets, leading to their sustained dominance. Europe is anticipated to grow at a rapid rate in the near future due to a large number of unexplored possibilities.

Asia Pacific is predicted to expand at a very high pace during the forecast period, from 2016 to 2024. In Japan and China, new and sophisticated immunotherapy medicines are being released. Several clinical trials are now underway in these nations, as well as FDA approvals for novel therapeutic compounds and combination treatments. The approval of new therapeutic medicines in countries like Japan and China is increasing the use of immunotherapy for tumor treatment.

Ongoing Research and Introduction of Novel Medication Classes to Spell Growth for the Market

In terms of cancer treatment options, cancer immunotherapy is expected to make significant development due to its superior efficacy over standard treatment methods. Because of very promising treatment techniques in the pipelines, the industry is expected to grow at a rapid pace in the next few years to come.

Immunotherapies that are under development are expected to offer additional treatment options and better results than already available treatments. The introduction of novel medication classes, including as histone deacetylase (HDAC) inhibitors and monoclonal antibodies, aimed against multiple myeloma receptors, is expected to impact the market in the forthcoming years. The global cancer immunotherapy market is expected to expand due to ongoing research on comparable medications with the goal of reducing side effects.

In addition, the industry has been boosted by the authorization of PD-1 and CTLA-4 checkpoint inhibitors for Non-Small Cell Lung Cancer (NSCLC) and melanoma. Innovative immunotherapy medication formulations, including as vaccines and adjuvants, are gaining popularity. In addition to that, additional immunotherapies, such as CAR T-cell treatment and immunomodulators, are being explored for improved outcomes. These new approvals and ongoing research are expected to boost market growth in the years to come.

The information provided in the review has been extracted from a TMR report titled “Cancer Immunotherapy Market (Therapy Type - Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, and Cancer Vaccines; Therapeutic Areas - Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, and Blood Cancers; End Users - Hospitals, ASC’s (Ambulatory Surgical Centers), and Cancer Research Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024”.

The global cancer immunotherapy market is segmented based on:

Therapy Type

  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
  • Immune System Modulators
  • Cancer Vaccines

Therapeutic Areas

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Melanoma
  • Blood Cancers

End Users

  • Hospitals
  • ASC’s (Ambulatory Surgical Centers)
  • Cancer Research Centers


  • Latin America
  • North America
  • Europe
  • Japan
  • Asia Pacific excluding Japan
  • Middle East and Africa

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”


Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453



7 of 10 large enterprizes view our Report to take the right decision.

View Report